Compare Nutanix Inc (NTNX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutanix Inc vs Viatris Inc — how do they compare? Nutanix Inc trades at $67 (market cap $18.10B), while Viatris Inc trades at $16.45 (market cap $18.95B). The key difference: Nutanix Inc and Viatris Inc are close in size by market cap, and Viatris Inc pays a 2.91% dividend while Nutanix Inc pays none. Which is the better fit depends on your goals.
| NTNX | VTRS | |
|---|---|---|
Market Cap | $18.10B | $18.95B |
Sector | Technology | Health |
52-Week High | $81.12 | $17.86 |
52-Week Low | $34.41 | $9.49 |
Enterprise Value | $17.25B | $31.07B |
Dividend Yield | — | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutanix (NTNX) trades at $67.49, down 0.84% on the day, with strong technical indicators showing a bullish trend. The company demonstrates robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.60 beating expectations of $0.49. Recent recognition in Gartner's Magic Quadrant for container management and strong conference presentations highlight ongoing business momentum. Valuation metrics show a P/E of 12.95 and P/S of 6.85, with exceptional profitability margins including 86.8% gross margin and 52.81% net income margin.
The outlook remains positive with analyst consensus price target of $77.20 representing 14% upside potential. Key opportunities include continued hybrid cloud adoption and AI infrastructure demand, while risks involve competitive pressures and execution challenges in maintaining growth momentum. Cash flow trends show improvement with 2026 operating cash flow projected at $917 million, supporting the company's strategic investments.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
